FMR reports 11.7% stake in Lexicon Pharmaceuticals
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
FMR LLC filed an amended Schedule 13G reporting significant ownership in Lexicon Pharmaceuticals, Inc. common stock. FMR LLC is shown as beneficially owning 51,782,044.66 shares, representing 11.7% of the outstanding common stock, with sole dispositive power over that amount.
Abigail P. Johnson is also reported as having sole dispositive power over the same 51,782,044.66 shares, equal to 11.7% of the class. Within this position, Fidelity Growth Company Commingled Pool holds 24,673,450 shares, described as 5.6% of Lexicon’s total outstanding common stock as of June 30, 2026.
Key Figures
Key Terms
beneficially owned financial
Sole Dispositive Power financial
Schedule 13G regulatory
Investment Company Act of 1940 regulatory
parent holding company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in LXRX does FMR LLC report on this Schedule 13G/A?
How much of Lexicon Pharmaceuticals (LXRX) stock is attributed to Abigail P. Johnson?
What is the position of Fidelity Growth Company Commingled Pool in LXRX?
Why is this Schedule 13G/A filing for Lexicon Pharmaceuticals (LXRX) significant?
AI-generated analysis. How Rhea-AI works. Not financial advice.